Source:http://linkedlifedata.com/resource/pubmed/id/14576058
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2004-2-3
|
| pubmed:abstractText |
Imatinib has pronounced but brief antileukemic activity in advanced Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+)ALL). We assessed the prognostic impact of pretreatment disease features and the early bone marrow (BM) response in 68 consecutive patients with Ph(+)ALL receiving imatinib salvage therapy. A complete hematologic or marrow response was achieved by 92% of patients with BM blasts below 5% on day 14, whereas 62.5% of patients with more than 5% BM blasts on day 14 were nonresponders. Similarly, time to progression (TTP) was superior in patients with a good day 14 response (5.2 versus 0.9 months; P <.0001). Prior complete remission of less than 6 months, white blood cell count of more than 10 x 10(9)/L, circulating peripheral blood blasts at diagnosis, additional Philadelphia chromosomes, or at least 2 Bcr-Abl fusion signals were associated with significantly inferior remission rate and response duration. In patients without poor prognostic features, single-agent imatinib may be appropriate before transplant salvage therapy. Conversely, patients with clinically or cytogenetically defined poor-risk features are candidates for trials of upfront imatinib in combination with other agents.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:AttaJohannesJ,
pubmed-author:BinckebanckAnjaA,
pubmed-author:BrückPatrickP,
pubmed-author:EhningerGerhardG,
pubmed-author:GökbugetNicolaN,
pubmed-author:GschaidmeierHaraldH,
pubmed-author:HoelzerDieterD,
pubmed-author:LeimerLotharL,
pubmed-author:LippThomasT,
pubmed-author:OttmannOliver GOG,
pubmed-author:PerzJolantaJ,
pubmed-author:PfeiferHeikeH,
pubmed-author:RiederHaraldH,
pubmed-author:ScheuringUrban JUJ,
pubmed-author:SchochClaudiaC,
pubmed-author:SchwerdtfegerRainerR,
pubmed-author:StelljesMatthiasM,
pubmed-author:WassmannBarbaraB
|
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
103
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1495-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:14576058-Adolescent,
pubmed-meshheading:14576058-Adult,
pubmed-meshheading:14576058-Aged,
pubmed-meshheading:14576058-Antineoplastic Agents,
pubmed-meshheading:14576058-Female,
pubmed-meshheading:14576058-Follow-Up Studies,
pubmed-meshheading:14576058-Humans,
pubmed-meshheading:14576058-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:14576058-Male,
pubmed-meshheading:14576058-Middle Aged,
pubmed-meshheading:14576058-Piperazines,
pubmed-meshheading:14576058-Predictive Value of Tests,
pubmed-meshheading:14576058-Pyrimidines,
pubmed-meshheading:14576058-Recurrence,
pubmed-meshheading:14576058-Remission Induction,
pubmed-meshheading:14576058-Survival Analysis
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.
|
| pubmed:affiliation |
Department of Hematology/Oncology, University Hospital Frankfurt, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|